Trump says drug tariffs key to pricing deals with industry, trading partners

The Trump administration is using the threat of tariff increases and offers of temporary carveouts to negotiate with both pharmaceutical companies and U.S. trading partners to push the industry to raise prices abroad, lower them in the U.S. and reshore manufacturing, beginning with a just-announced deal between the White House and Pfizer. President Trump, administration officials and Pfizer executives unveiled the first public agreement in the White House’s drug-price push during a Sept. 30 Oval Office press conference . Trump...